2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1226

Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets
Abstract Number: 749

Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis
Abstract Number: 478

Evaluation of the Relationship Between Methotrexate Polyglutamation and Efficacy in the Collagen-Induced Arthritis Mouse Model
Abstract Number: 1373

Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
Abstract Number: 2664

Evaluation of Thyroid Autoimmune Disease in Primary SjöGren’s Syndrome and Its Association with Disease Phenotype
Abstract Number: 155

Evaluation of Ultrasonography As Modality for Identification of Calcium Crystal Deposits in Patients of Primary Osteoarthritis of Knee Joint
Abstract Number: 775

Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina
Abstract Number: 1366

Evidence Based Criteria for Corticosteroid Tapering/Discontinuation. an Analysis of the Paediatric Rheumatology International Trials Organization (PRINTO) Trial in New Onset Juvenile Dermatomyositis
Abstract Number: 2184

Evidence Based Physical Activity Threshold to Predict Improved/High Function in Older Adults with Lower Extremity Conditions: The Osteoarthritis Initiative
Abstract Number: 1921

Evidence for Prevotella Copri As an Immune-Relevant Bacterium in Rheumatoid Arthritis
Abstract Number: 373

Evidence for TMJ Pain As a Component of a Generalized Pain Phenotype
Abstract Number: 3030

Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development
Abstract Number: 1516

Evidence of Labial Salivary Gland Epithelial Cell Activation from Patients with Rheumatoid Arthritis and Sicca Symptomatology
Abstract Number: 2274

Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2
Abstract Number: 2693

Evolution of Disease Activity over a 5-Year Period in the 395 Patients with Primary SjöGren’s Syndrome of the Assess Prospective Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].